Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
05/2003
05/01/2003US20030082189 Humanized neutralizing antibodies against hemolytic uremic syndrome
05/01/2003US20030082188 Treatment of prostate cancer by inhibitors of NCAM2
05/01/2003US20030082187 Combined cancer treatment methods using antibodies to aminophospholipids
05/01/2003US20030082186 Synthetic peptides that bind to the hepatitis B virus core and E antigens
05/01/2003US20030082180 Combination of compounds that inhibit the biological effects of tnf-alpha and cd95l in a medicament
05/01/2003US20030082179 Complexing antibody with poarathyroid hormone
05/01/2003US20030082175 April receptor (BCMA) and uses thereof
05/01/2003US20030082173 Screening drugs that block lymphocytes; genetic engineered rodent
05/01/2003US20030082172 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
05/01/2003US20030082166 Compounds and methods for modulating nonclassical cadherin-mediated functions
05/01/2003US20030082148 Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
05/01/2003CA2842429A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003CA2793019A1 Humanized antibodies
05/01/2003CA2675409A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003CA2470197A1 Mycobacterial genes down-regulated during latency
05/01/2003CA2464700A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
05/01/2003CA2464695A1 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003CA2464372A1 Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464338A1 Infectious salmon anaemia virus vaccine
05/01/2003CA2464239A1 Psma antibodies and protein multimers
05/01/2003CA2463960A1 Transient immortalization
05/01/2003CA2463893A1 Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
05/01/2003CA2461665A1 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
05/01/2003CA2461543A1 Sperm factor sequences
05/01/2003CA2460665A1 Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing them and their applications
05/01/2003CA2454361A1 Humanized antibodies
04/2003
04/30/2003CN1415016A Trichoderma reesei木聚糖酶 Trichoderma reesei xylanase
04/30/2003CN1415013A BASB059 polypeptides from neisseria meningitidis
04/30/2003CN1414976A Chimeric peptides used as immunogen and its antibody, and method for their use for immunization
04/30/2003CN1414975A Sex-chromosome-specific proteins, species specific and sperm specific protein and method for their identification and isolation
04/30/2003CN1414970A Transgenically produced fusion proteins
04/30/2003CN1414103A Human serine/threonine protein kitase, its coding sequence, preparation method and use
04/30/2003CN1414021A Desmocyte growth factor 13 antibody, antagonist and agonist
04/30/2003CN1414020A Desmocyte growth factor 11 antibody, antagonist and agonist
04/30/2003CN1414017A Preparation of anti cytoplasmic thymidine kinase-IgY and tumor diagnosis composition
04/30/2003CN1414016A Leptospira adventitial protein, its code sequence and use
04/30/2003CN1414015A Leptospira adventitial protein, its code sequence and use
04/30/2003CN1414014A Leptospira adventitial protein its code sequence and use
04/30/2003CN1107115C System for expression of heterologous antigens as fusion proteins
04/30/2003CN1107072C Programing cell death induced molecule II
04/30/2003CN1106858C Vaccine composition having antitumour activity and use there of in therapy of malignant diseases
04/29/2003US6555667 Hypoxia-regulated genes
04/29/2003US6555651 Ligand binding site of rage and uses thereof
04/29/2003US6555520 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferative and immunologicval disorders
04/29/2003US6555354 Enzymatic polypeptide for use in the treatment of inflammation, reperfusion injury, viral diseases, allergies, infections, pain, autoimmune,cardiovascular, nervous system, kidney, urogenital, sexual, kidney disorders
04/29/2003US6555352 Peptide for use in human therapeutics and diagnostic compositions
04/29/2003US6555338 Given nucleotide sequence; use of polynucleotides and polypeptides in diagnostic assays, and possibly functional genomics
04/29/2003US6555335 Xylanase from Trichoderma reesei , method for production thereof, and methods employing this enzyme
04/29/2003US6555329 Detecting a modulator of chromosomal stability during meiosis amd mitosis; obtain cell sample, incubate with modulator and substrate, monitor cell for adjustment in cell division
04/29/2003US6555327 Monoclonal antibodies against S100
04/29/2003US6555322 Connective tissue growth factor (CTGF); drug screening for agents that modulate the activity of a CTGF receptor comprising the alpha 2- macroglobulin receptor
04/29/2003US6555319 Antibodies for inhibiting blood coagulation and methods of use thereof
04/29/2003US6555316 Human g35030 gene; diagnostic kits; recombinant host cells
04/29/2003US6555313 Production of anti-self antibodies from antibody segment repertoires and displayed on phage
04/29/2003US6555310 Producing a multivalent polypeptide display library, starting from a library of phage including a phage capable of displaying from its outersurface a fusion protein of a coatin protein, an antibody variable domain and a tag
04/29/2003US6555113 Elevating the ratio of circulating HDL to circulating LDL by administering a peptide conjugate of a helper T cell epitope portion linked to a B cell epitope portion; decrease in development of atherosclerotic lesions
04/29/2003US6555111 Method of inhibiting the cytocidal effect of TNF with TNF receptor-specific antibodies
04/29/2003US6555110 Microencapsulated compounds and method of preparing same
04/29/2003CA2159098C Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
04/29/2003CA2105804C Kainate-binding, human cns receptors of the eaa5 family
04/29/2003CA2102208C Binding domains in notch and delta proteins
04/24/2003WO2003033710A1 Novel n-acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor
04/24/2003WO2003033680A2 Kinases and phosphatases
04/24/2003WO2003033677A2 Dimerized growth factor and materials and methods for producing it
04/24/2003WO2003033674A2 Human antibodies that have mn binding and cell adhesion-neutralizing activity
04/24/2003WO2003033670A2 Method for preparation of single chain antibodies
04/24/2003WO2003033666A2 Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
04/24/2003WO2003033654A2 Direct targeting binding proteins
04/24/2003WO2003033653A2 Affinity enhancement agents
04/24/2003WO2003033646A2 Compositions and methods for the modulation of viral maturation
04/24/2003WO2003033644A2 Peptide useful in immunomodulation
04/24/2003WO2003033538A1 Anti-hla-dr antibody
04/24/2003WO2003033537A1 Process for the production of egg yolk antibodies against organochlorine pesticides
04/24/2003WO2003033535A2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
04/24/2003WO2003032898A2 Modified human thymic stromal lymphopoietin
04/24/2003WO2003032814A2 Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
04/24/2003WO2003032813A2 Methods for the treatment of carcinoma
04/24/2003WO2003032810A2 Treatment and diagnosis of insulin resistant states
04/24/2003WO2003004049A3 Use of polyclonal anti-hiv goat serum as a therapeutic agent
04/24/2003WO2002098441A3 Method of treating metabolic disorders using neuronatin polypeptides
04/24/2003WO2002089841A3 Method of preventing cell death using antibodies to neural thread proteins
04/24/2003WO2002088706A3 Process for differential diagnosis of alzheimer's dementia and device therefor
04/24/2003WO2002088180A3 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
04/24/2003WO2002079429A3 Anti-muc-1 single chain antibodies for tumor targeting
04/24/2003WO2002072822A3 Als2 gene and amyotrophic lateral sclerosis type 2
04/24/2003WO2002066507A3 Histidine phosphatase interacting protein of 120 kd
04/24/2003WO2002055552A3 Soluble cyclic analogues of beta amyloid peptide
04/24/2003WO2002051870A3 Phage display libraries of human vh fragments
04/24/2003WO2002050120A3 High affinity antibodies
04/24/2003WO2002046383A3 Protein modification and maintenance molecules
04/24/2003WO2002046234A8 Cocaine haptens
04/24/2003WO2002046227A3 Glp-1 fusion proteins
04/24/2003WO2002030980A3 Use of anti-human integrin alpha d antibodies to treat spinal cord injury
04/24/2003WO2002026825A3 G-protein coupled receptors
04/24/2003WO2002009751A8 COMPOSITIONS FOR INDUCING SELF-SPECIFIC ANTI-IgE ANTIBODIES AND USES THEREOF
04/24/2003WO2002004513A3 Down syndrome critical region 1-like 1 proteins
04/24/2003WO2001078796A3 Type ii gonadotropin-releasing hormone receptor and polynucleotides encoding therefor
04/24/2003WO2001077389A3 Genes expressed in foam cell differentiation
04/24/2003WO2001075440A3 Schizophrenia related genes
1 ... 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 ... 1494